Search Results for "Khedezla"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Khedezla. Results 1 to 2 of 2 total matches.
See also: desvenlafaxine
In Brief: Khedezla - A New Brand of Desvenlafaxine
The Medical Letter on Drugs and Therapeutics • Jan 06, 2014 (Issue 1433)
In Brief: Khedezla - A New Brand of Desvenlafaxine ...
The FDA has approved the marketing of another extended-release brand-name formulation of the serotonin and norepinephrine reuptake inhibitor (SNRI) desvenlafaxine (Khedezla – Par/Osmotica) for treatment of depression. It is the third extended-release formulation of desvenlafaxine to become available in the US. Khedezla was approved using a 505(b)(2) application, a new drug application (NDA) that relies upon the FDA's findings of safety and/or effectiveness for a previously approved drug.Khedezla does not appear to offer any advantage over the other extended-release formulations of...
Levomilnacipran (Fetzima): A New SNRI for Depression
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013 (Issue 1432)
) $177.00
Desvenlafaxine base2 – 50 mg once/d 139.00
Khedezla (Par/Osmotica) 134.00
Duloxetine – Cymbalta ...
The FDA has approved levomilnacipran (lee" voe mil
na' si pran; Fetzima – Forest), a serotonin and norepinephrine
reuptake inhibitor (SNRI), for treatment of
major depressive disorder. Levomilnacipran is the
more active enantiomer of milnacipran (Savella), which
was approved in 2009 for management of fibromyalgia. Fetzima has not been studied in fibromyalgia.